ReviewFrontiers in immunology2026
Advancements in understanding and treating CXCL16/CXCR6 in tumors and in inflammatory diseases: a narrative review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CXCL16/CXCR6 axis exerts a multifaceted, bidirectional regulatory influence across various pathological processes, including neoplasms and inflammatory disorders. Its functions are notably context-dependent, possessing the capacity to both inhibit and facilitate disease progression. This article aims to systematically analyze this 'double-edged sword' characteristic by providing an exhaustive review of the axis's functional spectrum across different diseases. Initially, we explore its bidirectional regulatory mechanisms within the tumor microenvironment, emphasizing the influence of tumor heterogeneity and the distinct roles of CXCL16 isoforms (membrane-bound and soluble) in determining functional outcomes. Subsequently, we broaden the discussion to encompass inflammatory diseases, examining the axis's potential as a predictive marker in these conditions and presenting the latest insights into its role in diseases such as asthma. Additionally, we provide a review of current advancements in drug development targeting this axis and elucidate its mechanisms of action. Ultimately, the paper underscores that accurately identifying the critical nodes where the CXCL16/CXCR6 axis alters its function is the central challenge and opportunity for the development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.